James Larkin
A5076054848- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Cancer Genomics and Diagnostics
- Astronomy and Astrophysical Research
- Renal and related cancers
- Immunotherapy and Immune Responses
- Stellar, planetary, and galactic studies
- Adaptive optics and wavefront sensing
- Computational Drug Discovery Methods
- Colorectal Cancer Treatments and Studies
- Synthesis of Tetrazole Derivatives
- Economic and Financial Impacts of Cancer
- Pancreatic and Hepatic Oncology Research
- Galaxies: Formation, Evolution, Phenomena
- Synthesis and biological activity
- Astronomical Observations and Instrumentation
- Astrophysics and Star Formation Studies
- Click Chemistry and Applications
- HER2/EGFR in Cancer Research
- Brain Metastases and Treatment
- Astro and Planetary Science
- Astrophysical Phenomena and Observations
Royal Marsden NHS Foundation Trust
2016-2025
Royal Marsden Hospital
2016-2025
Institute of Cancer Research
2015-2025
Institute of Cancer Research
2012-2025
Memorial Sloan Kettering Cancer Center
2007-2024
Cornell University
2015-2024
Royal North Shore Hospital
2021-2024
Princess Alexandra Hospital
2019-2024
The Francis Crick Institute
2023-2024
Melanoma Institute Australia
2011-2024
Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] have been shown to complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or plus was compared with patients
Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates more than 50% in patients with metastatic melanoma V600E mutation.
Intratumor heterogeneity may foster tumor evolution and adaptation hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples.
The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits programmed cell death 1 (PD-1) and has antitumor activity in melanoma.In this randomized, controlled, phase 3 study, we assigned 834 melanoma a 1:1:1 ratio to receive pembrolizumab (at dose of 10 mg per kilogram body weight) every 2 weeks or four doses kilogram) weeks. Primary end points were progression-free overall survival.The estimated 6-month...
Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab everolimus carcinoma who had received previous treatment.
Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than alone phase 3 trial involving patients advanced melanoma. We now report 3-year overall outcomes this trial.
Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than a trial involving patients with advanced melanoma. We now report 5-year outcomes the trial.
In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses patients with advanced renal-cell carcinoma. This 3 trial involving previously untreated carcinoma compared the standard-of-care sunitinib.
Although a sizable body of knowledge is prerequisite to expert skill, that must be indexed by large numbers patterns that, on recognition, guide the in fraction second relevant parts store. The forms complex schemata can problem's interpretation and solution constitute part what we call physical intuition.
Activating mutations in serine–threonine protein kinase B-RAF (BRAF) are found 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared chemotherapy, but responses often short-lived. In previous trials, MEK inhibition appeared to be promising this population.
Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In United States, has also as adjuvant therapy melanoma on basis recurrence-free overall survival rates were higher than those with placebo in a phase 3 trial. We wanted to determine efficacy nivolumab versus patients resected this randomized, double-blind, trial, we randomly assigned 906 (≥15 years age) who undergoing complete resection stage IIIB, IIIC, or IV receive an...
The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset resistance observed inhibitors alone. This randomized phase 3 study evaluated combination inhibitor vemurafenib cobimetinib.We randomly assigned 495 previously untreated unresectable locally advanced metastatic V600 mutation-positive receive cobimetinib (combination group) placebo (control group). primary end point was investigator-assessed...
Combined BRAF and MEK inhibition, as compared with inhibition alone, delays the emergence of resistance reduces toxic effects in patients who have melanoma V600E or V600K mutations.
The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial evaluate as adjuvant therapy in resected, high-risk stage III melanoma.Patients completely resected melanoma were randomly assigned (with stratification according cancer geographic region) receive 200 mg of (514 patients) or placebo (505 intravenously every weeks for total 18 doses (approximately...
Background Activating mutations in serine–threonine protein kinase B-RAF (BRAF) are found 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared chemotherapy, but responses often short-lived. In previous trials, MEK inhibition appeared to be promising this population. Methods In phase 3 open-label trial, we randomly assigned 322 who had metastatic melanoma a V600E or V600K BRAF mutation receive either trametinib, an oral selective...
Combination therapy with the BRAF inhibitor dabrafenib plus MEK trametinib improved survival in patients advanced melanoma V600 mutations. We sought to determine whether adjuvant would improve outcomes resected, stage III mutations.In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 870 completely V600E or V600K mutations receive oral at a dose of 150 mg twice daily 2 once (combination therapy, 438 patients) two matched placebo tablets (432 for 12 months. The...
Purpose We conducted a retrospective analysis to assess the safety profile of nivolumab monotherapy in patients with advanced melanoma and describe management adverse events (AEs) using established guidelines. Patients Methods Safety data were pooled from four studies, including two phase III trials, who received 3 mg/kg once every 2 weeks. evaluated rate treatment-related AEs, time onset resolution select AEs (those potential immunologic etiology), impact suppressive immune-modulating...